Contrasting Enovis (NYSE:ENOV) and Pathfinder Cell Therapy (OTCMKTS:PFND)

Enovis (NYSE:ENOV) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Enovis and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-4.51%	3.98%	2.88%
Pathfinder Cell Therapy	N/A	N/A	N/A

Institutional & Insider Ownership

98.4% of Enovis shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Enovis and Pathfinder Cell Therapy’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$1.82 billion	1.26	-$33.26 million	($1.50)	-27.79
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Enovis.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Enovis and Pathfinder Cell Therapy, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	0	1	8	0	2.89
Pathfinder Cell Therapy	0	0	0	0	N/A

Enovis presently has a consensus price target of $71.63, suggesting a potential upside of 70.17%. Given Enovis’ higher possible upside, analysts plainly believe Enovis is more favorable than Pathfinder Cell Therapy.

Summary

Enovis beats Pathfinder Cell Therapy on 6 of the 8 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.